Education
About Us
Working with TipRanks
Follow Us
Alterity Therapeutics Ltd (ATHE)
NASDAQ:ATHE
ATHE Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.00 - $5.87
Previous CloseN/A
Volume131.33K
Average Volume (3M)24.04K
Market Cap
$32.18M
Enterprise Value$2.03M
Total Cash (Recent Filing)AU$2.88M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta1.18
Next Earnings
Feb 26, 2026EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.58
Shares Outstanding11,094,748
10 Day Avg. Volume18,334
30 Day Avg. Volume24,037
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$8.00Price Target Upside175.86% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
Alterity Therapeutics News
PremiumCompany Announcements
Alterity Therapeutics Completes Key Phase 2 Trial for MSA Treatment
PremiumCompany Announcements
Alterity Therapeutics Reports Progress and Financial Results
PremiumCompany Announcements
Alterity Therapeutics Announces Change in Substantial Holding
PremiumCompany Announcements
Alterity Therapeutics Expands Capital with New Securities Quotation
PremiumCompany Announcements
Alterity Therapeutics Issues Over 1 Billion New Shares
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsAlterity Therapeutics reported positive clinical results for its Phase 2 trial of ATH434 in Multiple System Atrophy, including 48% slowing of clinical progression at the 50 mg dose level.
Financial PerformanceAlterity announced it raised A$40M (~$24.8M in USD) through a two-tranche placement of its fully paid ordinary shares.
Regulatory ApprovalATH434 has orphan drug designation for MSA in both the US and EU, enhancing its potential marketability and regulatory support.
Bears Say
Stock RecommendationThe recommendation on ATHE shares is being lowered to Hold as these shares have exceeded the $4 price target.
---
Ownership Overview
―
Insiders
0.01% Mutual Funds
0.34% Other Institutional Investors
99.65% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
ATHE FAQ
What was Alterity Therapeutics Ltd’s price range in the past 12 months?
Alterity Therapeutics Ltd lowest stock price was $1.00 and its highest was $5.87 in the past 12 months.
What is Alterity Therapeutics Ltd’s market cap?
Alterity Therapeutics Ltd’s market cap is $32.18M.
When is Alterity Therapeutics Ltd’s upcoming earnings report date?
Alterity Therapeutics Ltd’s upcoming earnings report date is Feb 26, 2026 which is in 326 days.
How were Alterity Therapeutics Ltd’s earnings last quarter?
Alterity Therapeutics Ltd released its earnings results on Feb 28, 2025. The company reported -$0.136 earnings per share for the quarter, the consensus estimate of -$0.136 by $0.
Is Alterity Therapeutics Ltd overvalued?
According to Wall Street analysts Alterity Therapeutics Ltd’s price is currently Undervalued.
Does Alterity Therapeutics Ltd pay dividends?
Alterity Therapeutics Ltd does not currently pay dividends.
What is Alterity Therapeutics Ltd’s EPS estimate?
Alterity Therapeutics Ltd’s EPS estimate is -0.14.
How many shares outstanding does Alterity Therapeutics Ltd have?
Alterity Therapeutics Ltd has 11,094,748 shares outstanding.
What happened to Alterity Therapeutics Ltd’s price movement after its last earnings report?
Alterity Therapeutics Ltd reported an EPS of -$0.136 in its last earnings report, expectations of -$0.136. Following the earnings report the stock price went down -2.326%.
Which hedge fund is a major shareholder of Alterity Therapeutics Ltd?
Currently, no hedge funds are holding shares in ATHE
---
Alterity Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.00 (175.86% Upside)
$8.00 (175.86% Upside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
58.03%
12-Months-Change
Fundamentals
Return on Equity
-154.88%
Trailing 12-Months
Asset Growth
-56.88%
Trailing 12-Months
Company Description
Alterity Therapeutics Ltd
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 that has completed Phase IIa clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.
---
ATHE Stock 12 Month Forecast
Average Price Target
$8.00
▲(175.86% Upside)
Technical Analysis
Best Analysts Covering ATHE
1 Year
1 Year Success Rate
0/1 ratings generated profit
1 Year Average Return
-20.30%
reiterated a buy rating last month
Copying Michael Okunewitch's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -20.30% per trade.
---